s9 SYMPOSIA Tuesday, 10 May 1994 QUALITY ASSURANCE IN BRACHYTHERAPY Chair : H. Meertens Co-chair : U. Haverkamp 8.30 Quality assurance in HDR-brachytherapy of carcinoma of the cervix. H.T. Eich, U. Haverkamp, R. Potter, T.H. Knocke, G.M. Schmilowski (Germany) 8.40 HDR stepping source dosimetry: the EPR approach. 6. Schaeken, P. Scalliet (Belgium) 8.50 Tissue equivalent plastic scintillator probes: fast, precise 192 Ir after- loading dosimetry. Principles and clinical application. U. Quast, D. Fluhs, M. Heintz, F. Indenkampen, H. Kolanoski (Germany) 9.00 In vivo dosimetry with L-alanine: a feasibility study and possible applications in brachytherapy. J.P. Waaner, J.P. Delpech, F. Marchioni, F. Kuntz, G. Methlin (France) 9.10 Discussion 9.20 NCS-report : recommendations for the measurement of the strength of iridium 192 high dose rate sources. A.H.L. Aalbers, W.F.M. Brouwer, H. Meertens, J.J. Petersen, B. Schaeken, J.L.M. Venselaar, A.G. Visser (The Netherlands, Belgium) 9.30 Discussion 9.35 Early experience with a remote afterloading system for LDR-applications in the head and neck region. G.G. Grabenbauer, M.H. Seeaenschmiedt, L. Keilholz, M. Lotter, R.G. Muller (Germany) 9.45 Discussion 9.50 Quality assurance in brain implants: Consequences of geometric optimization of interstitial volume implants. J.K.Kolkman-Deurloo, A.G. Visser, N. Driver, P.C. Levendag (The Netherlands) 10.00 Discussion 10.05 Coffee Break 10.30 An audit of retrospective and contemporary brachytherapy doses in the treatment of cervical cancer. P.R. Blake, M. Wilkins, M. Bidmead (United Kingdom) 3 4 5 6 7 8 10.40 Discussion
Transcript
s9
SYMPOSIA
Tuesday, 10 May 1994
QUALITY ASSURANCE IN BRACHYTHERAPY
Chair : H. Meertens Co-chair : U. Haverkamp
8.30 Quality assurance in HDR-brachytherapy of carcinoma of the cervix. H.T. Eich, U. Haverkamp, R. Potter, T.H. Knocke, G.M. Schmilowski (Germany)
8.40 HDR stepping source dosimetry: the EPR approach. 6. Schaeken, P. Scalliet (Belgium)
8.50 Tissue equivalent plastic scintillator probes: fast, precise 192 Ir after- loading dosimetry. Principles and clinical application. U. Quast, D. Fluhs, M. Heintz, F. Indenkampen, H. Kolanoski (Germany)
9.00 In vivo dosimetry with L-alanine: a feasibility study and possible applications in brachytherapy. J.P. Waaner, J.P. Delpech, F. Marchioni, F. Kuntz, G. Methlin (France)
9.10 Discussion
9.20 NCS-report : recommendations for the measurement of the strength of iridium 192 high dose rate sources. A.H.L. Aalbers, W.F.M. Brouwer, H. Meertens, J.J. Petersen, B. Schaeken, J.L.M. Venselaar, A.G. Visser (The Netherlands, Belgium)
9.30 Discussion
9.35 Early experience with a remote afterloading system for LDR-applications in the head and neck region. G.G. Grabenbauer, M.H. Seeaenschmiedt, L. Keilholz, M. Lotter, R.G. Muller (Germany)
9.45 Discussion
9.50 Quality assurance in brain implants: Consequences of geometric optimization of interstitial volume implants. J.K.Kolkman-Deurloo, A.G. Visser, N. Driver, P.C. Levendag (The Netherlands)
10.00 Discussion
10.05 Coffee Break
10.30 An audit of retrospective and contemporary brachytherapy doses in the treatment of cervical cancer. P.R. Blake, M. Wilkins, M. Bidmead (United Kingdom)
3
4
5
6
7
8
10.40 Discussion
SlO
Tuesday, 10 May 1994
10.45
10.55
11 .oo
11.10
11.15
11.25 Discussion
11.30 Correlation between dose to rectum and bladder calculated utilizing radiographs and CT data. H. Meertens, F. van den Berg, A. Blom (The Netherlands)
11.40
11.45
Estimation of the dose the bladder receives in gynecologic brachytherapy with complete colpostat (selectron type). M.L. Petriz Gonzalez, C. Cinos, M.C. Fernandez, C. Gutierrez, M. Cambray, S. Villa, S. Marin, J.S. Pera (Spain)
Discussion
Brachytherapy applicators geometry influences the quality of pelvic dose distribution in cervical cancer patients. E. Senkus, A. Kobierska, J. Jassem, K. Serkies, A. Badzio (Poland)
Discussion
3-D-HDR afterloading therapy planning in cervix and endometrium cancer: the value of MR imaging in exact calculation of critical organ radiation exposure. B. Goetze, A. Ebert, B. Buchling, B. Hamm, H. Weitzel, V. Budach (Germany)
Discussion
Poster discussion
INTRAOPERATIVE BRACHYTHERAPY (BLADDER EXCLUDED)
Chair : Ch. Haie Co-chair : M.H. Seegenschmiedt
14.00 Comparison of three boost techniques (intra-operative, post-operative brachytherapy and external irradiation) in conservative treatment of breast cancer. C. Henneauin, M. Espie, E. Bourstyn, M. Levardon, P. Clot, L. Mignot, M. Marty, C. Maylin (France)
9
10
11
12
33
14.10 Discussion
14.15 Brachytherapy . in head and neck tumors with mould technique. A new development. L.E.C.M. Blank, P.F. Schouwenburg, D. Gonzalez-Gonzalez, J.B. De Boer, P.A. Voute, D. Kupperman (The Netherlands)
34
14.25 lntraoperative high dose rate brachytherapy for head and neck cancer. S. Naq, S. Dixit, R. Mountain, D. Schuller (U.S.A.)
35
Sll
14.35
14.45
14.55
15.05
15.15
15.25
15.30
15.40
15.45
Tuesday, 10 May 1994 _____________-------
Discussion
Soft tissue sarcomas. brachytherapy.
The role of intraoperative 36
L. Cionini, P. Olmi, S. Marzano, S. Mussari (Italy)
lntraoperative interstitial iridium brachytherapy in the treatment of soft tissue sarcomas. L. Thomas, M. Delannes, E. Stockle, P. Martel, J. Pigneux, N. Daly-Schveitzer, B.N. Bui, C. Chevreau, G. Kantor (France)
37
Discussion
Per-operative brachytherapy (PB) of prostate cancer: analysis of 64 cases and new perspectives. P. Montemaqqi, S. Luzi, A. Piermattei, D. Smaniotto, M. Giustacchini, N. Cellini (Italy)
38
Discussion
lntraoperative (IO) 125 I Brachytherapy (BRA) for recurrent tumors in previously operated and irradiated fields. P. Nickers, C. Bertrand, B. Mansvelt, A. de Neve, M.Th. Hoornaert, C. Mitine, M. Beauduin (Belgium)
39
Discussion
Coffee Break
PULSED HIGH-DOSE RATE EXPERIENCE IN BRACHYTHERAPY
Chair : P. Levenday Co-chair : S. Engelholm
16.00 Experimental studies of the equivalence of continuous low dose rate and pulsed low dose rate radiotherapy. 51 B. Erickson, D. Zellmer, J. Shadley, J. Moulder (U.S.A.)
16.05
16.15
Discussion
First experiences to compare classic LDR and PDR irradiation with help of the animal model guinea pig skin. A. Brock, W. Prager, S. Pohlmann (Germany)
52
16.25
16.30
Discussion
The Kiel experience in PDR interstitial and intracavitary brachytherapy. G. Kovacs, P. Kohr, R. Galalae, P. Dennert, H.M. Mehdorn, R. Rochels, B. Kremer, J. Werner, D. Weisner (Germany)
53
16.40 Discussion
s12
Tuesday, 10 May 1994 _________________
16.45 PDR optimized dose distributions versus non-optimized CLDR dose distributions on the basis of clinical examples. Ch. Berns, P. Fritz, F.W. Hensley, M. Wannenmacher (Germany)
54
16.55 Discussion
17.00 Fractionated brachytherapy in cancer of the head and neck. P.C. Levendag, A. Visser, P. Jansen (The Netherlands)
55
17.15 Discussion
17.20 Poster discussions
s13 Wednesday, 11 May 1994
-_--_-_--_-__-____
EQUIVALENT DOSE IN BRACHYTHERAPY
. Chair : Co-chair
9.00
E. P.
Lartigau Scalliet
Effects of uncertainties in LO-parameters on tumour control probabilities for PDR and HDR brachytherapy. A.G. Visser, G.J.M. van den Aardweg, P.C. Levendag (The Netherlands)
9.10
9.15
Discussion
Biological equivalence of low dose rate to multifractionated high dose rate irradiations: investigations in mouse lip mucosa. G. Stueben, W. Landuyt, A.J. van der Kogel, E. van der Schueren (Germany)
9.25
9.30
Discussion
A mathematical model of intraluminal brachytherapy. L.T. Tan, B. Jones, R. Dale, C. Bleasdale, S. Myint, J. Littler (United Kingdom)
9.40
9.45
Discussion
Estimation of repair kinetics in patients with breast adenocarcinoma. J.M. Simon, J.J. Mazeron, B. Dubray, P. Scalliet, J.P. Le Bourgeois (France)
9.55
10.00
Discussion
Clinical considerations in the design of new treatment strategies for HDR- and PDR- brachytherapy as an alternative for LDR-brachytherapy. L.A.M. Pop, J.F.C. van den Broek, A.J. van der Kogel (The Netherlands)
10.10
10.15
Discussion
Under which conditions would a HDR and a LDR gynecological treatment have the same biological effect ? P. Scalliet (Belgium)
10.25 Discussion
10.30 Coffee Break
61
62
63
64
65
66
s14 Wednesday, 11 May 1994
OPEN COMMUNICATIONS
Chair : Co-chair :
10.50
J. Hammer G.B. Pizzi
High-dose-rate (HDR) brachytherapy after percutaneous coronary angioplasty (PTCA). Preliminary dosimetric tests of a new source presentation for a non-oncological disease. G.Y. Popowski, V. Verin, P. Nouet, M. Rouzaud, E. Grob, M. Schwager, P. Urban, J. Kurtz, W. Rutishauser (Switzerland)
11 .oo
11.05
Discussion
Results of HDR-brachytherapy in the definitive treatment of endometrial carcinoma. Evaluation of 267 patients. T.-H. Knocke, H. Kucera, B. Weidinger, R. Potter (Germany)
11.15
11.20
Discussion
Postoperative vaginal irradiation with high dose rate brachytherapy in uterine carcinoma. I. Martel, P. Pommier, T. Bachelot, P. Romestaing, F.P. Rocher, J.M. Ardiet, J.P. Gerard (France]
11.30
11.35
Discussion
Accelerated hyperfractionated external and intracavitary radiotherapy as primary treatment of advanced cervix cancer - treatment technique and preliminary experiences. H. Annweiler, M. Stuschke, J. Kummermehr, H. Sack (Germany)
11.45
11.50
Discussion
Low dose rate interstitial brachytherapy for localized prostatic carcinomas N. Breteau, M. Peneau, A. Favre, R. Sabattier, H. Ibrahim, K. Tabbakh, D. Delavierre (France)
12.00
12.05
Discussion
Combined external gamma and intracavitary 252Cf neutron radiation therapy in the management of rectal cancer. V. Atkocius, A. Burneckis, E. Janulionis (Lithuania)
12.15
12.20
Discussion
The impact of the boost type (E, Ir-192 HDR) on the cosmetic result in conservative breast cancer treatment. J. Hammer, C. Track, B. Pakisch, D.H. Seewald, J.P. Zoidl, H. Leitner, W. Labeck, A. Hackel (Austria)
12.30 Discussion
71
72
73
74
75
76
77
s15
Wednesday, 11 May 1994 ______---_________
BRACHYTHERAPY IN BRONCHUS AND OESOPHAGUS CARCINOMA
Chair : Co-chair
14.00
14.10
14.15
14.25
14.30
14.40
14.45
14.55
15.00
15.10
15.15
15.25
15.30
16.00
. D. Kogelnik C. Hennequin
High dose rate brachytherapy (HDR BT) in the curative nonsurgical treatment of esophageal cancer (30 cases). P. Pommier, S. Bonvoisin, J.M. Ardiet, R. Coquard, F. Desseigne, X. Montbarbon, P. Romestaing, F. Mornex, J.P. Gerard (France)
Discussion
Extrapolated response doses in combined HDR brachytherapy and external beam irradiation in esophageal cancer treatment. B. Pakisch, H. Leitner, P. Kohek, E. Poier, G. Stucklschweiger, J. Poschauko, J. Hammer, A. Hack1 (Austria)
Discussion
Fractionated intraluminal HDR radiotherapy in palliative and curative treatment concepts for esophageal carcinoma. G.G. Grabenbauer, M.H. Seeaenschmiedt, R. Fietkau, J. Hochberger, R.G. Muller (Germany)
Discussion
Single-fraction intraluminal high-dose-rate radiotherapy for the palliation of dysphagia in advanced oesophageal cancer. M. Kulhavy, C.V. Levin, R.K. Sur (South Africa)
Discussion
lntraluminal irradiation in esophageal cancer: a prospective study. J.J. Jaaer, H. Langendijk, J. de Jong, J. Rijken, M. Pannebakker (The Netherlands)
Discussion
Contribution of HDR brachytherapy (BT) in the treatment of esophageal carcinomas: a 2 years experience. P. Mainaon, F. Bidault, C. Michiels, M.C. Bone-Lepinoy, I. Barillot, B. Coudert, J.C. Horiot (France)
Discussion
Coffee Break
Low dose rate versus high dose rate intraluminal brachytherapy for malignant endobronchial obstruction. T.C.M. Lo, L. Girshovich, G.A. Healey, J.F. Beamis (U.S.A.)
90
91
92
93
94
95
96
S16
16.10 Discussion
16.15 Curative irradiation for limited non small cell lung cancer with exclusive high dose rate brachytherapy (HDRBT) (28 patients). J.M. Ardiet, P. Pommier, R. Coquard, M. Perol, X. Montbarbon, P.J. Souquet, P. Romestaing, F. Mornex, J.P. Gerard (France)
16.25
16.30
16.40
16.45
16.55
17.00
Wednesday, 11 May 1994
97
Discussion
HDR brachytherapy and external beam radiotherapy in the treatment of stage Ills/b non small cell lung cancer. A two years experience. P. Muto, V. Ravo, G. Panelli (Italy1
Discussion
Endobronchial high-dose rate brachytherapy (HDR-BT) for lung carcinoma: results and complications in 1 1 1 patients (PTS). F.L. Reboul, B. Chauvet, P. Vincent, Y. Brewer, C. Felix-Faure, M. Taulelle (France)
